SeaStar Medical Holding Corporation (ICU)
NASDAQ: ICU · Real-Time Price · USD
1.250
0.00 (0.00%)
At close: Apr 23, 2025, 4:00 PM
1.290
+0.040 (3.20%)
Pre-market: Apr 24, 2025, 6:38 AM EDT
SeaStar Medical Holding Revenue
In the year 2024, SeaStar Medical Holding had annual revenue of $135.00K. SeaStar Medical Holding had revenue of $67.00K in the quarter ending December 31, 2024.
Revenue (ttm)
$135.00K
Revenue Growth
n/a
P/S Ratio
34.66
Revenue / Employee
$7,105
Employees
19
Market Cap
10.90M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 135.00K | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
ICU News
- 16 days ago - FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery - GlobeNewsWire
- 27 days ago - SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 weeks ago - SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 - GlobeNewsWire
- 5 weeks ago - NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award - PRNewsWire
- 2 months ago - SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market - GlobeNewsWire
- 3 months ago - SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial - GlobeNewsWire
- 3 months ago - FDA Approves Feasibility Study with SeaStar Medical's Selective Cytopheretic Device in Adults with Cardiorenal Syndrome - GlobeNewsWire
- 3 months ago - SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer - GlobeNewsWire